A detailed history of Adar1 Capital Management, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 93,284 shares of ATXS stock, worth $878,735. This represents 0.17% of its overall portfolio holdings.

Number of Shares
93,284
Previous 138,158 32.48%
Holding current value
$878,735
Previous $1.26 Billion 18.31%
% of portfolio
0.17%
Previous 0.24%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.97 - $12.65 $402,519 - $567,656
-44,874 Reduced 32.48%
93,284 $1.03 Billion
Q2 2024

Aug 13, 2024

BUY
$8.83 - $13.51 $1.18 Million - $1.8 Million
133,506 Added 2869.86%
138,158 $1.26 Billion
Q1 2024

May 15, 2024

SELL
$6.99 - $16.69 $1.3 Million - $3.11 Million
-186,599 Reduced 97.57%
4,652 $65.5 Million
Q4 2023

Feb 14, 2024

BUY
$4.42 - $8.06 $845,329 - $1.54 Million
191,251 New
191,251 $1.47 Billion

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $143M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.